Pipeline

Hexagon Bio is advancing a pipeline of next-generation ADCs with novel payloads that address unmet needs in solid tumors and hematological malignancies. Our lead programs leverage proprietary protein translation inhibitor payloads designed to overcome resistance and improve efficacy across multiple cancer types. These innovative therapies are currently in the preclinical stages, with candidates advancing toward clinical trials.